W
Wayne Shaw
Researcher at Janssen Pharmaceutica
Publications - 26
Citations - 7362
Wayne Shaw is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Canagliflozin & Type 2 diabetes. The author has an hindex of 17, co-authored 24 publications receiving 5476 citations. Previous affiliations of Wayne Shaw include Stanford University.
Papers
More filters
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Terrance D. Barrett,Michele A. Weidner-Wells,Hsiaowei Deng,David R. Matthews,Bruce Neal +11 more
TL;DR: Canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria in patients with type 2 diabetes.
Journal ArticleDOI
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W. Mahaffey,Bruce Neal,Vlado Perkovic,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Elisa Fabbrini,Tao Sun,Qiang Li,Mehul Desai,David R. Matthews +11 more
TL;DR: Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups.
Journal ArticleDOI
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Karin Rådholm,Karin Rådholm,Gemma A. Figtree,Vlado Perkovic,Vlado Perkovic,Scott D. Solomon,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Terrance D. Barrett,Wayne Shaw,Mehul Desai,David R. Matthews,Bruce Neal +13 more
TL;DR: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) as mentioned in this paper enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk and reported the effects on heart failure and cardiovascular death overall, in those with and without a baseline history of heart failure.
Journal ArticleDOI
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Bruce Neal,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Peter P. Stein,Mehul Desai,Wayne Shaw,Joel Jiang,Frank Vercruysse,Gary Meininger,David R. Matthews +11 more
TL;DR: The CANVAS trial as discussed by the authors evaluated the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk.